These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 17063397)
1. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Ramsay E; Alnajim J; Anantha M; Taggar A; Thomas A; Edwards K; Karlsson G; Webb M; Bally M Pharm Res; 2006 Dec; 23(12):2799-808. PubMed ID: 17063397 [TBL] [Abstract][Full Text] [Related]
2. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. Ramsay E; Alnajim J; Anantha M; Zastre J; Yan H; Webb M; Waterhouse D; Bally M Eur J Pharm Biopharm; 2008 Mar; 68(3):607-17. PubMed ID: 17904831 [TBL] [Abstract][Full Text] [Related]
3. Copper-topotecan complexation mediates drug accumulation into liposomes. Taggar AS; Alnajim J; Anantha M; Thomas A; Webb M; Ramsay E; Bally MB J Control Release; 2006 Aug; 114(1):78-88. PubMed ID: 16842880 [TBL] [Abstract][Full Text] [Related]
4. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Tardi PG; Gallagher RC; Johnstone S; Harasym N; Webb M; Bally MB; Mayer LD Biochim Biophys Acta; 2007 Mar; 1768(3):678-87. PubMed ID: 17208196 [TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Yang L; Cui F; Cun D; Tao A; Shi K; Lin W Int J Pharm; 2007 Aug; 340(1-2):163-72. PubMed ID: 17482779 [TBL] [Abstract][Full Text] [Related]
7. Formulation and comparative characterization of chitosan, gelatin, and chitosan-gelatin-coated liposomes of CPT-11-HCl. Shende P; Gaud R Drug Dev Ind Pharm; 2009 May; 35(5):612-8. PubMed ID: 18951273 [TBL] [Abstract][Full Text] [Related]
8. Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes. Dicko A; Frazier AA; Liboiron BD; Hinderliter A; Ellena JF; Xie X; Cho C; Weber T; Tardi PG; Cabral-Lilly D; Cafiso DS; Mayer LD Pharm Res; 2008 Jul; 25(7):1702-13. PubMed ID: 18320294 [TBL] [Abstract][Full Text] [Related]
9. The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™. Patankar N; Anantha M; Ramsay E; Waterhouse D; Bally M Pharm Res; 2011 Apr; 28(4):848-57. PubMed ID: 21181548 [TBL] [Abstract][Full Text] [Related]
10. Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes. Dicko A; Tardi P; Xie X; Mayer L Int J Pharm; 2007 Jun; 337(1-2):219-28. PubMed ID: 17270372 [TBL] [Abstract][Full Text] [Related]
11. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release. Li C; Cui J; Li Y; Wang C; Li Y; Zhang L; Zhang L; Guo W; Wang J; Zhang H; Hao Y; Wang Y Eur J Pharm Sci; 2008 Aug; 34(4-5):333-44. PubMed ID: 18573336 [TBL] [Abstract][Full Text] [Related]
12. High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma. Owens TS; Dodds H; Fricke K; Hanna SK; Crews KR J Chromatogr B Analyt Technol Biomed Life Sci; 2003 May; 788(1):65-74. PubMed ID: 12668072 [TBL] [Abstract][Full Text] [Related]
13. Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH. Joguparthi V; Anderson BD J Pharm Sci; 2008 Jan; 97(1):433-54. PubMed ID: 17918731 [TBL] [Abstract][Full Text] [Related]
14. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. Rivory LP; Robert J J Chromatogr B Biomed Appl; 1994 Nov; 661(1):133-41. PubMed ID: 7866541 [TBL] [Abstract][Full Text] [Related]
15. Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method. Stano P; Bufali S; Pisano C; Bucci F; Barbarino M; Santaniello M; Carminati P; Luisi PL J Liposome Res; 2004; 14(1-2):87-109. PubMed ID: 15461935 [TBL] [Abstract][Full Text] [Related]
16. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38. Sadzuka Y; Hirotsu S; Hirota S Jpn J Cancer Res; 1999 Feb; 90(2):226-32. PubMed ID: 10189894 [TBL] [Abstract][Full Text] [Related]
17. Modified hydrolysis kinetics of the active lactone moiety of 10-hydroxycamptothecin by liposomal encapsulation. Shi K; Tian Y; Jiang Y; Wang L; Cui F Pharm Dev Technol; 2010 Dec; 15(6):644-52. PubMed ID: 19943738 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253 [TBL] [Abstract][Full Text] [Related]
20. Stability of irinotecan-loaded drug eluting beads (DC Bead) used for transarterial chemoembolization. Kaiser J; Thiesen J; Krämer I J Oncol Pharm Pract; 2010 Mar; 16(1):53-61. PubMed ID: 19617306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]